| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 61.75% | Truist Securities | → $17 | Reiterates | Buy → Buy |
| 10/02/2023 | 61.75% | Needham | → $17 | Reiterates | Buy → Buy |
| 08/14/2023 | 71.27% | Stephens & Co. | → $18 | Reiterates | Overweight → Overweight |
| 07/03/2023 | 33.21% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 06/30/2023 | 61.75% | Stifel | $15 → $17 | Maintains | Buy |
| 06/30/2023 | 33.21% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 06/30/2023 | 33.21% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
| 06/30/2023 | 42.72% | Credit Suisse | $13 → $15 | Maintains | Neutral |
| 06/30/2023 | 61.75% | Needham | $15 → $17 | Maintains | Buy |
| 06/26/2023 | 42.72% | Needham | → $15 | Reiterates | Buy → Buy |
| 06/22/2023 | 33.21% | Morgan Stanley | → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 05/24/2023 | 56.99% | B of A Securities | → $16.5 | Upgrades | Neutral → Buy |
| 05/01/2023 | 52.24% | DA Davidson | $14 → $16 | Maintains | Buy |
| 04/28/2023 | 71.27% | Guggenheim | $16 → $18 | Maintains | Buy |
| 04/28/2023 | 33.21% | Morgan Stanley | $11 → $14 | Maintains | Equal-Weight |
| 04/28/2023 | 23.69% | Credit Suisse | → $13 | Reiterates | → Neutral |
| 04/28/2023 | 71.27% | Canaccord Genuity | $14 → $18 | Maintains | Buy |
| 04/28/2023 | 42.72% | Needham | → $15 | Reiterates | → Buy |
| 04/25/2023 | 23.69% | Credit Suisse | $11 → $13 | Maintains | Neutral |
| 04/21/2023 | 23.69% | Wells Fargo | $10 → $13 | Maintains | Equal-Weight |
| 04/12/2023 | 71.27% | Stephens & Co. | → $18 | Initiates Coverage On | → Overweight |
| 03/28/2023 | 37.96% | B of A Securities | $12.5 → $14.5 | Maintains | Neutral |
| 03/23/2023 | 52.24% | Guggenheim | → $16 | Upgrades | Neutral → Buy |
| 02/09/2023 | 33.21% | Jefferies | → $14 | Downgrades | Buy → Hold |
| 02/02/2023 | 42.72% | Raymond James | → $15 | Initiates Coverage On | → Outperform |
| 01/30/2023 | 33.21% | Truist Securities | $12 → $14 | Maintains | Buy |
| 01/06/2023 | 4.66% | Morgan Stanley | $12 → $11 | Maintains | Equal-Weight |
| 10/12/2022 | -4.85% | Wells Fargo | $8 → $10 | Maintains | Equal-Weight |
| 10/07/2022 | 52.24% | Goldman Sachs | $14.5 → $16 | Maintains | Buy |
| 10/07/2022 | 4.66% | Credit Suisse | $9 → $11 | Maintains | Neutral |
| 10/07/2022 | 23.69% | SVB Leerink | $8 → $13 | Maintains | Market Perform |
| 10/04/2022 | 23.69% | Piper Sandler | $12 → $13 | Maintains | Overweight |
| 10/04/2022 | 42.72% | Needham | $12 → $15 | Maintains | Buy |
| 10/03/2022 | 42.72% | Canaccord Genuity | $12 → $15 | Maintains | Buy |
| 09/21/2022 | 37.96% | Goldman Sachs | $13 → $14.5 | Maintains | Buy |
| 09/14/2022 | 14.18% | Morgan Stanley | $9 → $12 | Maintains | Equal-Weight |
| 09/08/2022 | 14.18% | Piper Sandler | → $12 | Assumes | → Overweight |
| 09/07/2022 | 42.72% | Truist Securities | → $15 | Initiates Coverage On | → Buy |
| 08/12/2022 | 52.24% | DA Davidson | → $16 | Initiates Coverage On | → Buy |
| 07/05/2022 | -23.88% | Wells Fargo | $6 → $8 | Maintains | Equal-Weight |
| 07/01/2022 | 14.18% | Canaccord Genuity | $17 → $12 | Maintains | Buy |
| 07/01/2022 | 23.69% | Goldman Sachs | $15 → $13 | Maintains | Buy |
| 05/26/2022 | 42.72% | Goldman Sachs | $26 → $15 | Maintains | Buy |
| 05/02/2022 | -42.91% | Wells Fargo | → $6 | Upgrades | Underweight → Equal-Weight |
| 04/29/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 04/29/2022 | -14.37% | B of A Securities | $45 → $9 | Downgrades | Buy → Neutral |
| 04/29/2022 | 4.66% | Piper Sandler | $22 → $11 | Maintains | Overweight |
| 04/29/2022 | 14.18% | Needham | $33 → $12 | Maintains | Buy |
| 04/29/2022 | -23.88% | SVB Leerink | $52 → $8 | Downgrades | Outperform → Market Perform |
| 04/29/2022 | -14.37% | Morgan Stanley | $30 → $9 | Downgrades | Overweight → Equal-Weight |
| 04/29/2022 | -14.37% | Credit Suisse | $33 → $9 | Downgrades | Outperform → Neutral |
| 04/11/2022 | -14.37% | Wells Fargo | → $9 | Initiates Coverage On | → Underweight |
| 04/07/2022 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 03/03/2022 | 213.99% | Credit Suisse | $43 → $33 | Maintains | Outperform |
| 02/11/2022 | 204.47% | Goldman Sachs | → $32 | Initiates Coverage On | → Buy |
| 01/11/2022 | 185.44% | Morgan Stanley | $31 → $30 | Maintains | Overweight |
| 01/11/2022 | 213.99% | Needham | $56 → $33 | Maintains | Buy |
| 12/17/2021 | 194.96% | Morgan Stanley | $56 → $31 | Maintains | Overweight |
| 12/02/2021 | 213.99% | Jefferies | → $33 | Initiates Coverage On | → Buy |
| 10/11/2021 | 432.83% | Morgan Stanley | $68 → $56 | Maintains | Overweight |
| 10/08/2021 | 489.91% | Credit Suisse | $63 → $62 | Maintains | Outperform |
| 10/08/2021 | 432.83% | Needham | $68 → $56 | Maintains | Buy |
| 10/08/2021 | 394.77% | SVB Leerink | $58 → $52 | Maintains | Outperform |
| 09/30/2021 | 480.4% | Berenberg | → $61 | Initiates Coverage On | → Buy |
| 09/17/2021 | 413.8% | Baird | $58 → $54 | Upgrades | Neutral → Outperform |
| 07/09/2021 | 547% | Needham | $59 → $68 | Maintains | Buy |
| 07/07/2021 | 566.03% | Credit Suisse | $59 → $70 | Maintains | Outperform |
| 07/02/2021 | 547% | Morgan Stanley | $60 → $68 | Maintains | Overweight |
| 05/28/2021 | 413.8% | Baird | → $54 | Initiates Coverage On | → Neutral |
| 05/06/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 04/15/2021 | 461.37% | Needham | → $59 | Initiates Coverage On | → Buy |
| 04/06/2021 | 470.88% | Morgan Stanley | $57 → $60 | Maintains | Overweight |
| 02/16/2021 | 470.88% | Piper Sandler | $57 → $60 | Maintains | Overweight |
| 01/15/2021 | 470.88% | Credit Suisse | $45 → $60 | Upgrades | Neutral → Outperform |
| 01/15/2021 | 432.83% | SVB Leerink | $53 → $56 | Maintains | Market Perform |
| 01/08/2021 | 328.16% | Credit Suisse | $42 → $45 | Maintains | Neutral |
| 01/08/2021 | 404.28% | SVB Leerink | $44 → $53 | Maintains | Market Perform |
| 01/07/2021 | 423.31% | BTIG | → $55 | Initiates Coverage On | → Buy |
| 12/08/2020 | 461.37% | Canaccord Genuity | → $59 | Initiates Coverage On | → Buy |
| 11/17/2020 | 356.71% | Stifel | → $48 | Initiates Coverage On | → Buy |
| 10/16/2020 | 356.71% | Morgan Stanley | $37 → $48 | Maintains | Overweight |
| 10/15/2020 | 385.25% | B of A Securities | $45 → $51 | Maintains | Buy |
| 10/15/2020 | 318.65% | SVB Leerink | $40 → $44 | Maintains | Market Perform |
| 10/08/2020 | 328.16% | B of A Securities | $42.5 → $45 | Maintains | Buy |
| 09/22/2020 | 328.16% | DA Davidson | → $45 | Initiates Coverage On | → Buy |
| 08/14/2020 | 280.59% | Credit Suisse | $38 → $40 | Maintains | Neutral |
| 08/14/2020 | 280.59% | SVB Leerink | $34 → $40 | Maintains | Market Perform |
| 07/27/2020 | 252.05% | B of A Securities | → $37 | Initiates Coverage On | → Buy |
| 07/27/2020 | 261.56% | Credit Suisse | → $38 | Initiates Coverage On | → Neutral |
| 07/27/2020 | 223.5% | SVB Leerink | → $34 | Initiates Coverage On | → Market Perform |
| 07/27/2020 | 252.05% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 271.08% | Goldman Sachs | → $39 | Initiates Coverage On | → Buy |
| 07/27/2020 | 328.16% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
What is the target price for Accolade (ACCD)?
The latest price target for Accolade (NASDAQ: ACCD) was reported by Truist Securities on October 2, 2023. The analyst firm set a price target for $17.00 expecting ACCD to rise to within 12 months (a possible 61.75% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Accolade (ACCD)?
The latest analyst rating for Accolade (NASDAQ: ACCD) was provided by Truist Securities, and Accolade reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Accolade (ACCD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Accolade, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Accolade was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
Is the Analyst Rating Accolade (ACCD) correct?
While ratings are subjective and will change, the latest Accolade (ACCD) rating was a reiterated with a price target of $0.00 to $17.00. The current price Accolade (ACCD) is trading at is $10.51, which is within the analyst's predicted range.